JP2023508375A5 - - Google Patents

Info

Publication number
JP2023508375A5
JP2023508375A5 JP2022538860A JP2022538860A JP2023508375A5 JP 2023508375 A5 JP2023508375 A5 JP 2023508375A5 JP 2022538860 A JP2022538860 A JP 2022538860A JP 2022538860 A JP2022538860 A JP 2022538860A JP 2023508375 A5 JP2023508375 A5 JP 2023508375A5
Authority
JP
Japan
Application number
JP2022538860A
Other languages
Japanese (ja)
Other versions
JPWO2021133749A5 (https=
JP2023508375A (ja
JP7712274B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066504 external-priority patent/WO2021133749A1/en
Publication of JP2023508375A publication Critical patent/JP2023508375A/ja
Publication of JPWO2021133749A5 publication Critical patent/JPWO2021133749A5/ja
Publication of JP2023508375A5 publication Critical patent/JP2023508375A5/ja
Application granted granted Critical
Publication of JP7712274B2 publication Critical patent/JP7712274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538860A 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換ピペラジン誘導体 Active JP7712274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911053559 2019-12-23
IN201911053559 2019-12-23
PCT/US2020/066504 WO2021133749A1 (en) 2019-12-23 2020-12-22 Substituted piperazine derivatives useful as t cell activators

Publications (4)

Publication Number Publication Date
JP2023508375A JP2023508375A (ja) 2023-03-02
JPWO2021133749A5 JPWO2021133749A5 (https=) 2023-12-07
JP2023508375A5 true JP2023508375A5 (https=) 2023-12-07
JP7712274B2 JP7712274B2 (ja) 2025-07-23

Family

ID=74191942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538860A Active JP7712274B2 (ja) 2019-12-23 2020-12-22 T細胞アクティベーターとして有用な置換ピペラジン誘導体

Country Status (11)

Country Link
US (1) US12454531B2 (https=)
EP (1) EP4081522A1 (https=)
JP (1) JP7712274B2 (https=)
KR (1) KR20220120624A (https=)
CN (1) CN115175907B (https=)
AU (1) AU2020412698A1 (https=)
BR (1) BR112022012222A2 (https=)
CA (1) CA3162979A1 (https=)
IL (1) IL294270A (https=)
MX (1) MX2022007130A (https=)
WO (1) WO2021133749A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023122772A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
CN114437127B (zh) * 2022-01-28 2023-12-22 万华节能科技(烟台)有限公司 一种基于氧化膦衍生物改性异氰酸酯化合物及其合成方法
EP4472963A1 (en) * 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
KR20240156394A (ko) 2022-03-01 2024-10-29 인실리코 메디신 아이피 리미티드 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
CN116969943A (zh) * 2022-04-28 2023-10-31 轩竹生物科技股份有限公司 三并环类二酰甘油激酶抑制剂及其用途
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
AR131786A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinación de anticuerpos ccr8 con inhibidores de dgk

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JP2544939B2 (ja) 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
WO2004002960A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
JP2006521400A (ja) 2003-03-26 2006-09-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病及び関連障害の処置のための化合物及びそれらの使用
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
EP1656376A1 (en) 2003-08-22 2006-05-17 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US7381401B2 (en) 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007114239A1 (ja) * 2006-03-30 2007-10-11 Sapporo Medical University DGKα阻害剤を含有する抗癌剤
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ido阻害剤
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110281908A1 (en) 2008-10-06 2011-11-17 Emory University Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス,インコーポレーテッド B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
NO2694640T3 (https=) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
WO2019062733A1 (zh) 2017-09-28 2019-04-04 南京药捷安康生物科技有限公司 Pde9 抑制剂及其用途
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
PT3814347T (pt) * 2018-06-27 2023-07-18 Bristol Myers Squibb Co Compostos de naftiridinona úteis como ativadores de células t
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
JPWO2020071550A1 (ja) 2018-10-04 2021-09-24 京都薬品工業株式会社 Cdk8阻害剤およびその用途
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN115210225A (zh) 2019-11-28 2022-10-18 拜耳公司 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론

Similar Documents

Publication Publication Date Title
JP2023508375A5 (https=)
CN305531623S (https=)
CN305527815S (https=)
CN305536250S (https=)
CN305534551S (https=)
CN305533470S (https=)
CN305533155S (https=)
CN305532811S (https=)
CN305532742S (https=)
CN305532648S (https=)
CN305531935S (https=)
CN305531483S (https=)
CN305531345S (https=)
CN305531086S (https=)
CN305530283S (https=)
CN305530228S (https=)
CN306026428S (https=)
CN306020241S (https=)
CN306003458S (https=)
CN305980678S (https=)
CN305965535S (https=)
CN305965149S (https=)
CN305949962S (https=)
CN305948181S (https=)
CN305947181S (https=)